Cancer 11 items
Studies
- Mendelian randomization finds CETP inhibition uniquely associated with increased breast cancer risk among lipid-lowering drug targets (Cancer Causes Control 2024)
- Mendelian randomisation links genetically raised HDL and LDL cholesterol, including a CETP locus signal, to higher breast cancer risk (PLoS Med 2020)
- Knocking down CETP shrinks triple-negative breast cancer xenografts by 86% and restores tamoxifen sensitivity in resistant cells (IUBMB Life 2024)
- Mendelian randomisation finds genetically higher CETP levels associated with increased non-endometrioid endometrial carcinoma risk (Front Endocrinol 2024)
- Evacetrapib suppresses colorectal cancer cell growth by blocking Wnt/beta-catenin signaling and activating JNK (Biol Pharm Bull 2022)
- Colorectal cancer patients have higher CETP activity and lower LCAT and PON-1 activity, with CETP mass an independent risk predictor (Clin Biochem 2019)
- CETP knockout sensitizes estrogen-receptor-positive breast cancer cells to cholesterol-depleting cytotoxic agents (Genes Cancer 2016)
- CETP is over-expressed in non-small cell lung cancer and obicetrapib restores ferroptosis sensitivity in xenografts and organoids (Clin Transl Med 2026)
- A review positions CETP alongside PCSK9 and ANGPTL3 as emerging lipid-regulatory targets in cancer, though CETP-specific oncology research remains scarce (Biomolecules 2026)
- Repurposed as a cancer drug: evacetrapib blocks a CEA-KRT1 interaction that drives oxaliplatin resistance in gastric cancer (Drug Resist Updat 2025)
- CETP localizes to germinal centre B cells and their neoplastic lymphoma counterparts (Histopathology 2004)